Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - therapeutics
340
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Small Molecule Inhibitors of the p38/MK2 Protein Interaction
Application New class of small molecule inhibitors with therapeutic potential for inflammatory diseases through disruption of the p38/MK2 protein-protein interaction. Key Benefits Therapeutic potential and utility for various inflammatory diseases. May have potentially fewer off-target effects and dose-limiting toxicities. May serve as a foundation...
Published: 7/10/2026
|
Updated: 7/9/2026
|
Inventor(s):
Andrey Ivanov
,
Haian Fu
Keywords(s):
Immunology and Inflammation Treatments
,
Neurology and Pain Treatments
,
Small Molecule
,
Therapeutics
Category(s):
TechPub Algolia >
Therapeutics
CD73-PROTACs for Cancer Therapy
SHORT DESCRIPTION A novel first-in-class proteolysis targeting chimera (PROTAC) that selectively degrades CD73 to reverse tumor immune evasion and inhibit cancer progression. INVENTORS Bin Zhang* Northwestern University Feinberg School of Medicine, Department of Medicine (Hematology & Oncology) Gary Schiltz* Weinberg...
Published: 7/6/2026
|
Updated: 7/6/2026
|
Inventor(s):
Keywords(s):
BIO2026
,
Breast cancer
,
Cancer/Oncology
,
Colon cancer
,
Lung cancer
,
Melanoma
,
PROTAC
,
Targeted therapy
,
Therapeutics
,
TPD - Targeted protein degradation
Category(s):
Life Sciences >
Therapeutics
Polycomb Repressive Complex 1 (PRC1) Inhibitors to Restore Immune Response in B-Cell Lymphomas
SHORT DESCRIPTION A therapeutic approach that restores MHC-II expression using PRC1 inhibitors to reactivate anti-tumor immunity in B-cell lymphomas. INVENTORS Lu Wang* Zibo Zhao * Principal Investigator NU Tech ID: NU 2025-010 IP STATUS U.S. Provisional Patent Application has been filed.
THERAPEUTICS
...
Published: 6/25/2026
|
Updated: 6/23/2026
|
Inventor(s):
Keywords(s):
Cancer/Oncology
,
Immunotherapy
,
Therapeutics
Category(s):
Life Sciences >
Therapeutics
Compositions and Methods for Enhanced Mitochondrial Delivery for Regenerative Therapies
SHORT DESCRIPTION A novel peptide coating process that improves mitochondrial cell uptake, preserves function, and enables targeted delivery for cardiovascular and regenerative therapies. NU Tech ID NU 2025-055 INVENTORS Bin Jiang* Northwestern University Feinberg School of Medicine, Department of Surgery (Vascular...
Published: 6/18/2026
|
Updated: 6/18/2026
|
Inventor(s):
Keywords(s):
BIO2026
,
Cardiology and Cardiovascular disease
,
MI - Myocardial Infarction
,
Neurodegenerative disease
,
Regenerative medicine
,
Targeted therapy
,
Therapeutics
,
Vascular disease
,
Vascular repair
Category(s):
Life Sciences >
Therapeutics
FTY720 for Treatment of Marfan Syndrome
NU2025-219 INVENTORS Tsutomu Kume* Can Tan SHORT DESCRIPTION This invention provides a novel use for FTY720, also known as Fingolimod, for the treatment and prevention of myxomatous degeneration of the mitral valve (MDMV) in Marfan syndrome. BACKGROUND Marfan syndrome, a genetic connective tissue disorder, frequently leads to MDMV, a severe...
Published: 6/18/2026
|
Updated: 6/18/2026
|
Inventor(s):
Keywords(s):
Cardiology and Cardiovascular disease
,
Repurposed Drugs
,
Therapeutics
Category(s):
Life Sciences >
Therapeutics
Inhibitors of TRIP8b for Novel Mood Disorder
Therapeutics
SHORT DESCRIPTION Novel inhibitors that disrupt TRIP8b-HCN binding to offer an alternative antidepressant mechanism for treatment of mood disorders. INVENTORS Gary Schiltz* Weinberg College of Arts and Sciences, Department of Chemistry Dane Chetkovich Ye Han Iredia Iyamu Kyle Lyman *...
Published: 6/17/2026
|
Updated: 6/17/2026
|
Inventor(s):
Keywords(s):
Antidepressant
,
BIO2026
,
Depression
,
Mood disorder
,
Neurologic disease
,
Neurology
,
Psychiatric disorder
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences >
Therapeutics
Bioactive Supramolecular Peptide Amphiphile Platforms for CNS In Vitro Models, CNS Regeneration, and Neurotherapeutic Delivery
SHORT DESCRIPTION A suite of self‑assembling peptide amphiphile nanostructures and hydrogels that mimic key neurotrophic factors, modulate ionic and electrical microenvironments, and protect therapeutic peptides to enhance neural survival, maturation, and regeneration across CNS diseases and injuries INVENTORS Samuel I Stupp Weinberg...
Published: 7/1/2026
|
Updated: 6/16/2026
|
Inventor(s):
Keywords(s):
AD - Alzheimer’s Disease
,
ALS - Amyotrophic Lateral Sclerosis
,
BIO2026
,
Biomaterials
,
CNS - Central Nervous System
,
Drug delivery
,
Drug discovery
,
Drug screening
,
Hydrogel
,
In vitro models
,
Neurology
,
PD - Parkinson's Disease
,
Regenerative medicine
,
Research tool
,
Scaffold
,
SCI - Spinal cord injury
,
Smart/Functional materials
,
Therapeutics
Category(s):
Life Sciences > Healthcare Devices, Tools & IT > Neurology
,
Life Sciences >
Therapeutics
Protein Degraders of NSD2 for Targeted Treatment of Head and Neck Cancers
SHORT DESCRIPTION Targeted protein degraders that selectively eliminate NSD2 for improved treatment of head and neck cancers. INVENTORS Gary Schiltz* Weinberg College of Arts and Sciences, Department of Chemistry Yanis Boumber * Principal Investigator NU Tech ID: NU 2023-140 IP STATUS U.S....
Published: 6/16/2026
|
Updated: 6/16/2026
|
Inventor(s):
Keywords(s):
BIO2026
,
Cancer/Oncology
,
Head and neck cancer
,
PROTAC
,
Small molecule
,
Targeted protein degradation
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences >
Therapeutics
Neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and neurodegenerative disorders
NU 2016-137B INVENTORS Richard Silverman Weinberg College of Arts and Sciences, Department of Chemistry SHORT DESCRIPTION Novel highly selective neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and other cancers with high expression of nNOS (e.g., gliomas, ovarian cancer) as well as neurodegenerative...
Published: 6/17/2026
|
Updated: 6/16/2026
|
Inventor(s):
Keywords(s):
AD - Alzheimer’s Disease
,
ALS - Amyotrophic Lateral Sclerosis
,
AUTM26C1
,
BIAUTM1
,
BIO2026
,
Cancer/Oncology
,
HD - Huntington's Disease
,
Melanoma
,
Neurodegenerative disease
,
Neuroinflammation
,
Neurologic disease
,
nNOS
,
PD - Parkinson's Disease
,
Small molecule
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences >
Therapeutics
Peptide Linkers for Modulating Antigen Immune Response in Cancer Vaccines
SHORT DESCRIPTION A novel non-biologically derived peptide linker technology enabling precise intracellular release of vaccine antigens to enhance immune activation. NU TECH ID NU 2024-124 INVENTORS Chad Mirkin* Weinberg College of Arts and Sciences, Department of Chemistry Tanner Fink *...
Published: 6/16/2026
|
Updated: 6/16/2026
|
Inventor(s):
Keywords(s):
BIO2026
,
Cancer/Oncology
,
Immunology
,
Immunotherapy
,
Infectious disease
,
Therapeutics
,
Vaccine
Category(s):
Life Sciences >
Therapeutics
1
2
3
4
5
6
7
8
9
10
...